Travis McDevitt-Galles, Tricia L. Fry, Katherine L. D. Richgels, Daniel A. Grear
{"title":"Rapid Risk Assessment Framework to Estimate Potential for Spillback at Human–Wildlife Interfaces","authors":"Travis McDevitt-Galles, Tricia L. Fry, Katherine L. D. Richgels, Daniel A. Grear","doi":"10.1155/tbed/4334954","DOIUrl":null,"url":null,"abstract":"<div>\n <p>More than 60% of emerging infectious diseases of humans have a wildlife origin, and when these diseases spread through human populations to new geographical areas, there is a considerable risk of spillback from humans to wildlife species. Spillback events can have severe consequences for wildlife populations, where the disease may cause morbidity and mortality, and human populations, where the establishment in wildlife may lead to prolonged transmission or new exposures in humans. Mitigating these consequences requires identifying the key risk factors that lead to human–wildlife transmission events and implementing risk-reducing actions, a challenge given that cross-species transmission events are rare and often data deficient. To identify potential species and locations that are most likely to lead to these rare events, we developed a spatially explicit, rapid risk assessment framework that incorporates three components of the spillback process: wildlife susceptibility, wildlife exposure, and pathogen introduction pressure. To demonstrate the broad applicability of our framework, we conducted a rapid risk assessment on two recent emerging zoonotic pathogens in humans, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mpox, to determine the relative spillback risk to wild mammalian species in the continental United States. The rapid risk assessment identified both species and locations with higher than expected spillback risk, providing managers and researchers with valuable information to prioritize surveillance and risk-mitigation actions. Our framework represents a rapid and flexible approach to assess the risks of spillback to wildlife populations during rapidly evolving zoonotic disease outbreaks.</p>\n </div>","PeriodicalId":234,"journal":{"name":"Transboundary and Emerging Diseases","volume":"2025 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbed/4334954","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transboundary and Emerging Diseases","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/tbed/4334954","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
More than 60% of emerging infectious diseases of humans have a wildlife origin, and when these diseases spread through human populations to new geographical areas, there is a considerable risk of spillback from humans to wildlife species. Spillback events can have severe consequences for wildlife populations, where the disease may cause morbidity and mortality, and human populations, where the establishment in wildlife may lead to prolonged transmission or new exposures in humans. Mitigating these consequences requires identifying the key risk factors that lead to human–wildlife transmission events and implementing risk-reducing actions, a challenge given that cross-species transmission events are rare and often data deficient. To identify potential species and locations that are most likely to lead to these rare events, we developed a spatially explicit, rapid risk assessment framework that incorporates three components of the spillback process: wildlife susceptibility, wildlife exposure, and pathogen introduction pressure. To demonstrate the broad applicability of our framework, we conducted a rapid risk assessment on two recent emerging zoonotic pathogens in humans, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mpox, to determine the relative spillback risk to wild mammalian species in the continental United States. The rapid risk assessment identified both species and locations with higher than expected spillback risk, providing managers and researchers with valuable information to prioritize surveillance and risk-mitigation actions. Our framework represents a rapid and flexible approach to assess the risks of spillback to wildlife populations during rapidly evolving zoonotic disease outbreaks.
期刊介绍:
Transboundary and Emerging Diseases brings together in one place the latest research on infectious diseases considered to hold the greatest economic threat to animals and humans worldwide. The journal provides a venue for global research on their diagnosis, prevention and management, and for papers on public health, pathogenesis, epidemiology, statistical modeling, diagnostics, biosecurity issues, genomics, vaccine development and rapid communication of new outbreaks. Papers should include timely research approaches using state-of-the-art technologies. The editors encourage papers adopting a science-based approach on socio-economic and environmental factors influencing the management of the bio-security threat posed by these diseases, including risk analysis and disease spread modeling. Preference will be given to communications focusing on novel science-based approaches to controlling transboundary and emerging diseases. The following topics are generally considered out-of-scope, but decisions are made on a case-by-case basis (for example, studies on cryptic wildlife populations, and those on potential species extinctions):
Pathogen discovery: a common pathogen newly recognised in a specific country, or a new pathogen or genetic sequence for which there is little context about — or insights regarding — its emergence or spread.
Prevalence estimation surveys and risk factor studies based on survey (rather than longitudinal) methodology, except when such studies are unique. Surveys of knowledge, attitudes and practices are within scope.
Diagnostic test development if not accompanied by robust sensitivity and specificity estimation from field studies.
Studies focused only on laboratory methods in which relevance to disease emergence and spread is not obvious or can not be inferred (“pure research” type studies).
Narrative literature reviews which do not generate new knowledge. Systematic and scoping reviews, and meta-analyses are within scope.